Sugi Predict

Sugi Predict / Compounds / SCHEMBL868598

SCHEMBL868598

SCHEMBL868598

Clc1ccc2c(n1)CCNC2

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PNMT P11086 8/20 0.47
▸ CYP3A4 P08684 1/20 0.44
▸ ADRA2A P08913 2/20 0.42
▸ ADRA2B P18089 2/20 0.42
▸ ADRA2C P18825 2/20 0.42
▸ ASIC3 Q9UHC3 2/20 0.41
▸ CD44 P16070 1/20 0.41
▸ MAOB P27338 1/20 0.41
▸ HTR2C P28335 3/20 0.39
▸ POLB P06746 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ F10 P00742 1/20 0.38
▸ HTR2B P41595 2/20 0.38
▸ HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1017773 0.98 PNMT (0.46) PNMTCYP3A4ADRA2AADRA2BADRA2C
Hydrochloric Acid SCHEMBL31226197 0.98 PNMT (0.46) PNMTCYP3A4ADRA2AADRA2BADRA2C
SCHEMBL4203489 0.86 HTR2C (0.47) PNMTADRA2AADRA2BADRA2CHTR2C
SCHEMBL29361127 0.85 PNMT (0.47) PNMTADRA2AADRA2BADRA2CASIC3
Hydrochloric Acid SCHEMBL15282909 0.85 HTR2C (0.46) PNMTADRA2AADRA2BADRA2CHTR2C
SCHEMBL12691385 0.85 PNMT (0.47) PNMTADRA2AADRA2BADRA2CASIC3
Hydrochloric Acid SCHEMBL12541304 0.83 PNMT (0.47) PNMTADRA2AADRA2BADRA2CASIC3
SCHEMBL868555 0.82 CHRNB2 (0.38) PNMTASIC3HTR2CHTR2BHTR2A
SCHEMBL30101445 0.82 CHRNB2 (0.38) PNMTASIC3HTR2CHTR2BHTR2A
SCHEMBL12696301 0.81 CYP3A4 (0.44) PNMTCYP3A4ADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3870566-B1 PD-1/PD-L1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-06 — — EP disclosed
US-20260001876-A1 Compounds and Their Use as PDE4 Activators MIRONID LIMITED (GB) 2026-01-01 — — US disclosed
US-12486273-B2 Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease HOFFMANN-LA ROCHE INC. (US) 2025-12-02 — — US disclosed
EP-4572761-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS Mironid Limited (GB) 2025-06-25 — — EP disclosed
WO-2025101780-A1 PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF OCTANT, INC. (US) 2025-05-15 — — WO disclosed
CN-119730854-A Compounds and their use as PDE4 activators 米罗尼德有限公司 2025-03-28 — — CN disclosed
CN-112955435-B PD-1/PD-L1 inhibitors 吉利德科学公司 2024-09-06 — — CN disclosed
CN-114728976-B Hydrogen-1H-pyrrolo [1,2-a ] pyrazine compounds for the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2024-08-16 — — CN disclosed
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
WO-2024038129-A1 COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS MIRONID LIMITED (GB) 2024-02-22 — — WO disclosed
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines PFIZER INC. 2004-09-30 — — US disclosed
US-6653302-B2 Benign prostatic hyperplasia PFIZER INC. 2003-11-25 — — US disclosed
US-20030130259-A1 Quinoline and quinazoline compounds useful in therapy FOX DAVID NATHAN ABRAHAM (GB) 2003-07-10 — — US disclosed
EP-0968208-B1 QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PFIZER LTD (GB) 2003-06-04 — — EP disclosed
US-6521629-B2 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia PFIZER INC. 2003-02-18 — — US disclosed
US-20020040028-A1 Quinoline and quinazoline compounds useful in therapy FOX DAVID NATHAN ABRAHAM (GB) 2002-04-04 — — US disclosed
US-6365599-B1 FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA PFIZER, INC. 2002-04-02 — — US disclosed
US-6169093-B1 FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PFIZER INC. 2001-01-02 — — US disclosed
EP-0968208-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA Pfizer Limited (GB) 2000-01-05 — — EP disclosed
WO-1998030560-A1 QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA PFIZER LIMITED (GB) 1998-07-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN PNMT 3390/4885CYP3A4 35/4885ADRA2A 229/4885
US-20260001876-A1 Compounds and Their Use as PDE4 Activators PDE4A, PDE4B, PDE7A PNMT 1421/4885CYP3A4 295/4885ADRA2A 53/4885
US-20030130259-A1 Quinoline and quinazoline compounds useful in therapy NQO2, RFT1, LPXN PNMT 2028/4885CYP3A4 115/4885ADRA2A 258/4885
US-20020040028-A1 Quinoline and quinazoline compounds useful in therapy BPHL, LPXN, NQO2 PNMT 2036/4885CYP3A4 115/4885ADRA2A 277/4885
US-12486273-B2 Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease AQP1, HRH2, HRH1 PNMT 2331/4885CYP3A4 2969/4885ADRA2A 1783/4885
US-20040192698-A1 Substituted 4-amino[1,2,4]triazolo[4,3-a] quinoxalines CYP4B1, CYP3A4, CYP1B1 PNMT 1622/4885CYP3A4 2/4885ADRA2A 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.